Praxis Precision Medicines, Inc. – NASDAQ:PRAX
Praxis Precision Medicines stock price today
$44.79
-32.21
-41.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Praxis Precision Medicines stock price monthly change
+51.34%
month
Praxis Precision Medicines stock price quarterly change
+51.34%
quarter
Praxis Precision Medicines stock price yearly change
+235.22%
year
Praxis Precision Medicines key metrics
Market Cap | 1.41B |
Enterprise value | N/A |
P/E | -0.2 |
EV/Sales | N/A |
EV/EBITDA | 0.06 |
Price/Sales | N/A |
Price/Book | 0.56 |
PEG ratio | N/A |
EPS | -15.91 |
Revenue | 2.19M |
EBITDA | -129.95M |
Income | -125.37M |
Revenue Q/Q | -36.89% |
Revenue Y/Y | 221.37% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -5920.32% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePraxis Precision Medicines stock price history
Praxis Precision Medicines stock forecast
Praxis Precision Medicines financial statements
| Jun 2023 | 781K | -34.31M | -4393.34% |
|---|---|---|---|
| Sep 2023 | 468K | -24.63M | -5263.25% |
| Dec 2023 | 515K | -26.87M | -5219.03% |
| Mar 2024 | 431K | -39.55M | -9177.03% |
| Mar 2024 | 431K | -39.55M | -9177.03% |
|---|---|---|---|
| Sep 2025 | 100K | -24.37M | -24373.59% |
| Oct 2025 | 246.2K | -34.54M | -14032.8% |
| Dec 2025 | 246.2K | -32.55M | -13221.81% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 133498000 | 27.87M | 20.88% |
|---|---|---|---|
| Sep 2023 | 106725000 | 19.96M | 18.71% |
| Dec 2023 | 87948000 | 18.27M | 20.78% |
| Mar 2024 | 250409000 | 20.72M | 8.28% |
| Jun 2023 | -31.21M | 5M | 69.67M |
|---|---|---|---|
| Sep 2023 | -23.21M | 0 | -1K |
| Dec 2023 | -23.86M | -50K | 4.12M |
| Mar 2024 | -20.58M | -91.22M | 182.48M |
Praxis Precision Medicines alternative data
| Aug 2023 | 109 |
|---|---|
| Sep 2023 | 109 |
| Oct 2023 | 109 |
| Nov 2023 | 109 |
| Dec 2023 | 109 |
| Jan 2024 | 109 |
| Feb 2024 | 109 |
| Mar 2024 | 82 |
| Apr 2024 | 82 |
| May 2024 | 82 |
| Jun 2024 | 82 |
| Jul 2024 | 82 |
Praxis Precision Medicines other data
30.65%
-69.00%
of PRAX is owned by hedge funds
44
-60
14.12M
-31.48M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 13427 |
| Patent |
|---|
Application Filling date: 1 May 2020 Issue date: 8 Sep 2022 |
Application METHODS OF TREATING SUBSTANCE ABUSE DISORDER, DYSPNEA, TINNITUS, AND CHILD AND ADOLESCENT DEPRESSION Filling date: 31 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 1 May 2020 Issue date: 18 Aug 2022 |
Application Filling date: 10 Jul 2020 Issue date: 4 Aug 2022 |
Application Filling date: 23 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 4 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 2 Nov 2021 Issue date: 5 May 2022 |
Application Filling date: 4 Mar 2020 Issue date: 28 Apr 2022 |
Grant Utility: Ion channel modulators Filling date: 29 May 2020 Issue date: 22 Mar 2022 |
Grant Utility: Compounds and their methods of use Filling date: 15 Aug 2018 Issue date: 22 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2022 9 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 28 Feb 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 7 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Marcio Souza M.B.A. (1979) Pres, Chief Executive Officer & Director | $1,440,000 |
| Dr. Bernard Ravina (1967) Chief Medical Officer | $799,810 |
| Ms. Nicole Sweeny (1975) Chief Commercial Officer | $310,900 |
Praxis Precision Medicines: Long List Of Failures And Mixed Data
Praxis: Shaking The Dust Off Calcium Channel Blockers For Essential Tremor
Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Compass Pathways: Psychedelics For Mental Health
Praxis Precision Medicines: Genetic Medicines For Neurological Disease
-
What's the price of Praxis Precision Medicines stock today?
One share of Praxis Precision Medicines stock can currently be purchased for approximately $44.79.
-
When is Praxis Precision Medicines's next earnings date?
Unfortunately, Praxis Precision Medicines's (PRAX) next earnings date is currently unknown.
-
Does Praxis Precision Medicines pay dividends?
No, Praxis Precision Medicines does not pay dividends.
-
How much money does Praxis Precision Medicines make?
Praxis Precision Medicines has a market capitalization of 1.41B.
-
What is Praxis Precision Medicines's stock symbol?
Praxis Precision Medicines, Inc. is traded on the NASDAQ under the ticker symbol "PRAX".
-
What is Praxis Precision Medicines's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Praxis Precision Medicines?
Shares of Praxis Precision Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Praxis Precision Medicines's key executives?
Praxis Precision Medicines's management team includes the following people:
- Mr. Marcio Souza M.B.A. Pres, Chief Executive Officer & Director(age: 46, pay: $1,440,000)
- Dr. Bernard Ravina Chief Medical Officer(age: 58, pay: $799,810)
- Ms. Nicole Sweeny Chief Commercial Officer(age: 50, pay: $310,900)
-
How many employees does Praxis Precision Medicines have?
As Jul 2024, Praxis Precision Medicines employs 82 workers.
-
When Praxis Precision Medicines went public?
Praxis Precision Medicines, Inc. is publicly traded company for more then 4 years since IPO on 16 Oct 2020.
-
What is Praxis Precision Medicines's official website?
The official website for Praxis Precision Medicines is praxismedicines.com.
-
Where are Praxis Precision Medicines's headquarters?
Praxis Precision Medicines is headquartered at 99 High Street, Boston, MA.
-
How can i contact Praxis Precision Medicines?
Praxis Precision Medicines's mailing address is 99 High Street, Boston, MA and company can be reached via phone at +61 73008460.
Praxis Precision Medicines company profile:
Praxis Precision Medicines, Inc.
praxismedicines.comExchange:
NASDAQ
Full time employees:
82
Industry:
Biotechnology
Sector:
Healthcare
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
99 High Street
Boston, MA 02110
Boston, MA 02110
CIK: 0001689548
ISIN: US74006W2070
CUSIP: 74006W108
